Fresenius Medical Care (FMS) Cut to Equal Weight at Morgan Stanley

Fresenius Medical Care (NYSE:FMS) was downgraded by investment analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report released on Monday, Marketbeat reports.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada restated a “hold” rating and issued a $44.00 target price on shares of Fresenius Medical Care in a research note on Wednesday, September 13th. Zacks Investment Research lowered shares of Fresenius Medical Care from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, DZ Bank restated a “buy” rating on shares of Fresenius Medical Care in a research note on Monday, November 13th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $48.50.

Shares of Fresenius Medical Care (NYSE:FMS) traded up $0.37 during trading on Monday, hitting $51.65. 167,100 shares of the stock were exchanged, compared to its average volume of 180,936. The firm has a market cap of $31,802.04, a price-to-earnings ratio of 23.16, a PEG ratio of 2.32 and a beta of 0.45. The company has a current ratio of 1.22, a quick ratio of 0.98 and a debt-to-equity ratio of 0.55. Fresenius Medical Care has a 1-year low of $39.46 and a 1-year high of $51.66.

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its position in shares of Fresenius Medical Care by 13.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 92,150 shares of the company’s stock valued at $3,882,000 after buying an additional 11,257 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Fresenius Medical Care by 205.4% during the 2nd quarter. SG Americas Securities LLC now owns 31,039 shares of the company’s stock valued at $1,500,000 after buying an additional 20,875 shares during the last quarter. BB&T Securities LLC grew its position in shares of Fresenius Medical Care by 1.4% during the 2nd quarter. BB&T Securities LLC now owns 15,053 shares of the company’s stock valued at $727,000 after buying an additional 211 shares during the last quarter. Intrust Bank NA grew its position in shares of Fresenius Medical Care by 21.1% during the 3rd quarter. Intrust Bank NA now owns 16,865 shares of the company’s stock valued at $825,000 after buying an additional 2,934 shares during the last quarter. Finally, Roundview Capital LLC bought a new stake in shares of Fresenius Medical Care during the 2nd quarter valued at about $391,000. 3.03% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Fresenius Medical Care (FMS) Cut to Equal Weight at Morgan Stanley” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/12/11/fresenius-medical-care-fms-rating-lowered-to-equal-at-morgan-stanley.html.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply